回应特朗普(Trump)的药物价格推力, 美国制毒者将价格压低至80%, 并发起直接销售以降低成本, U.S. drugmakers slashed prices up to 80% and launched direct sales to cut costs, responding to Trump’s drug price push.

2025年,包括AstraZeneca、Pfizer、Novo Nordisk、Sanofi和Bristol-Myers Squibb在内的美国主要毒品制造者宣布直接对消费者进行销售和大幅降价,回应特朗普总统降低毒品成本的推动。 In 2025, major U.S. drugmakers including AstraZeneca, Pfizer, Novo Nordisk, Sanofi, and Bristol-Myers Squibb announced direct-to-consumer sales and steep price cuts, responding to President Trump’s push to lower drug costs. 公司提供的折扣高达80%,固定价格如Ozempic每月499美元,胰岛素每月35美元,不论保险情况如何。 Companies offered discounts of up to 80%, fixed prices like $499 monthly for Ozempic, or $35 per month for insulin, regardless of insurance. 有些人,如辉瑞,把较低的价格与关税减免和美国投资挂钩。 Some, like Pfizer, tied lower prices to tariff relief and U.S. investment. 政府计划在2026年推出TrumpRx.gov,而PhRMA将推出AmericasMedicines.com以简化直接采购. The government plans to launch TrumpRx.gov in 2026, while PhRMA will debut AmericasMedicines.com to streamline direct purchases. 在降低美国高处方药价格的持续努力中,这些行动针对没有保险、保险不足和成本敏感的病人。 These moves target uninsured, under-insured, and cost-sensitive patients amid ongoing efforts to reduce America’s high prescription drug prices.